Biotechnology
Technology
Health

Pluristem Therapeutics

$3.62
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (3.13%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell PSTI and other stocks, options, ETFs, and crypto commission-free!

About PSTI

Pluristem Therapeutics, Inc. Common Stock, also called Pluristem Therapeutics, is a biotechnology company, which engages in the provision of cell therapy development. Read More It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others. Its products include PLacental eXpanded, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Employees
180
Headquarters
Haifa, Haifa
Founded
2001
Market Cap
55.43M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
109.33K
High Today
$3.70
Low Today
$3.46
Open Price
$3.49
Volume
32.95K
52 Week High
$13.80
52 Week Low
$3.24

Collections

Biotechnology
Technology
Health
Therapy
Asia (Non-China)
Asia

PSTI News

ReutersJul 31

Pluristem gets positive results from radiation treatment trials

12

PSTI Earnings

-$0.09
$0.08
$0.24
$0.41
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Sep 11, After Hours

More PSTI News

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.